NewsRx

Search our medical news database

Parkinson Disease

Drug development company reports positive Parkinson disease study results

Published in Gene Therapy Weekly, November 4th, 2004

Neurologix Inc. (OTCBB:NRGX) announced the presentation of data showing that the company's NLX-P101 is well tolerated and effective in a primate model of Parkinson disease.

David Eidelberg, MD, director of the Susan and Leonard Feinstein Center for Neurosciences in the Institute for Medical Research at North Shore-Long Island Jewish Health System and professor of Neurology and Neurosurgery at New York University School of Medicine, presented the results at the 18th Annual Symposia on Etiology, Pathogenesis, and Treatment of Parkinson disease and other Movement Disorders at the Sheraton Center Toronto Hotel, in Toronto, Ontario.

The findings presented...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook